Tevogen Appoints Interim Leaders for Five Verticals to Unlock $50M Revenue
Tevogen appointed interim leaders across five core business verticals—Digital Health, Generics, Contract Research, Biotech and Artificial Intelligence—to drive its first-phase diversified growth strategy. The company is evaluating strategic acquisitions expected to operate as subsidiaries generating more than $50 million annually, with transactions slated to close by Q2 2026.
1. Interim Leadership Appointments
Tevogen appointed interim leaders across its five core business verticals: Arpita Patel and Wojtek Stobinski for Digital Health; Sadiq Khan and David Banko for Generics; William Keane for Contract Research; Lori Grosso for Biotech; and Mittul Mehta for Artificial Intelligence. These designations establish accountability and specialized oversight for each segment during the initial phase of the company’s diversified growth strategy.
2. Diversified Growth Strategy
In this first phase, Tevogen is evaluating strategic opportunities to establish new subsidiaries expected to collectively generate over $50 million in annual revenues. The company anticipates completing customary due diligence and executing definitive agreements to close these transactions by the second quarter of 2026.
3. Future Business Initiatives
Tevogen’s broader roadmap leverages its AI-driven drug development platform and precision T cell therapy expertise to explore domestic generics, biosimilars, medical devices and innovative insurance solutions. These initiatives support Tevogen’s mission to enhance affordability and efficiency in healthcare through scalable, scientifically rigorous innovations.